124 related articles for article (PubMed ID: 28443705)
1. Severity of Withdrawal Symptoms, Plasma Oxytocin Levels, and Treatment Outcome in Heroin Users Undergoing Acute Withdrawal.
Nikolaou K; Kapoukranidou D; Ndungu S; Floros G; Kovatsi L
J Psychoactive Drugs; 2017; 49(3):233-241. PubMed ID: 28443705
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Oxytocin on Withdrawal, Craving and Stress Response in Heroin-Dependent Patients: A Randomized, Double-Blind Clinical Trial.
Moeini M; Omidi A; Sehat M; Banafshe HR
Eur Addict Res; 2019; 25(1):41-47. PubMed ID: 30630161
[TBL] [Abstract][Full Text] [Related]
3. The Association between the Level of Plasma Oxytocin and Craving among Former Heroin Users.
Lin SH; Chen PS; Lee LT; Lee SY; Tsai HC; Chen WT; Chen KC; Lee IH; Lu RB; Yang YK
Eur Addict Res; 2018; 24(2):71-78. PubMed ID: 29902803
[TBL] [Abstract][Full Text] [Related]
4. Relationship between plasma cortisol levels, withdrawal symptoms and craving in abstinent and treated heroin addicts.
Nava F; Caldiroli E; Premi S; Lucchini A
J Addict Dis; 2006; 25(2):9-16. PubMed ID: 16785214
[TBL] [Abstract][Full Text] [Related]
5. Brain-derived neurotrophic factor serum levels in heroin-dependent patients after 26weeks of withdrawal.
Zhang K; Jiang H; Zhang Q; Du J; Wang Y; Zhao M
Compr Psychiatry; 2016 Feb; 65():150-5. PubMed ID: 26774004
[TBL] [Abstract][Full Text] [Related]
6. Prediction of withdrawal symptoms during opioid detoxification.
Dijkstra BA; Krabbe PF; De Jong CA; van der Staak CP
J Opioid Manag; 2008; 4(5):311-9. PubMed ID: 19070269
[TBL] [Abstract][Full Text] [Related]
7. Time-dependent neuroendocrine alterations and drug craving during the first month of abstinence in heroin addicts.
Shi J; Li SX; Zhang XL; Wang X; Le Foll B; Zhang XY; Kosten TR; Lu L
Am J Drug Alcohol Abuse; 2009; 35(5):267-72. PubMed ID: 19591065
[TBL] [Abstract][Full Text] [Related]
8. Association between cholesterol plasma levels and craving among heroin users.
Lin SH; Yang YK; Lee SY; Hsieh PC; Chen PS; Lu RB; Chen KC
J Addict Med; 2012 Dec; 6(4):287-91. PubMed ID: 22895461
[TBL] [Abstract][Full Text] [Related]
9. Tramadol versus buprenorphine for the management of acute heroin withdrawal: a retrospective matched cohort controlled study.
Threlkeld M; Parran TV; Adelman CA; Grey SF; Yu J
Am J Addict; 2006; 15(2):186-91. PubMed ID: 16595358
[TBL] [Abstract][Full Text] [Related]
10. Plasma catecholamines during an ultrarapid heroin detoxification.
Macedo TR; Relvas J; Fontes Ribeiro CA ; Pacheco F; Morgadinho MT; Pinto CM; Gomes PC; Ventura M; Henriques V; Nunes SV; Ruis GR; Ramalheira C; Boto I; Vale LL
Ann N Y Acad Sci; 2000 Sep; 914():303-10. PubMed ID: 11085330
[TBL] [Abstract][Full Text] [Related]
11. Increased oxytocin levels among abstinent heroin addicts: Association with aggressiveness, psychiatric symptoms and perceived childhood neglect.
Gerra LM; Gerra G; Mercolini L; Manfredini M; Somaini L; Pieri CM; Antonioni M; Protti M; Ossola P; Marchesi C
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Apr; 75():70-76. PubMed ID: 28093220
[TBL] [Abstract][Full Text] [Related]
12. Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine.
Malcolm BJ; Polanco M; Barsuglia JP
J Psychoactive Drugs; 2018; 50(3):256-265. PubMed ID: 29608409
[TBL] [Abstract][Full Text] [Related]
13. Neuro-Immuno-Endocrine Interactions in Early Life Stress and Heroin Withdrawal Timeline.
Moeini M; Esmaeil N; Mokhtari HR; Eskandari N; Banafshe HR
Eur Addict Res; 2020; 26(1):28-39. PubMed ID: 31630140
[TBL] [Abstract][Full Text] [Related]
14. [Is premature termination of opiate detoxification due to intensive withdrawal or craving?].
Scherbaum N; Heppekausen K; Rist F
Fortschr Neurol Psychiatr; 2004 Jan; 72(1):14-20. PubMed ID: 14745685
[TBL] [Abstract][Full Text] [Related]
15. Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial.
Morabbi MJ; Razaghi E; Moazen-Zadeh E; Safi-Aghdam H; Zarrindast MR; Vousoghi N; Akhondzadeh S
Int Clin Psychopharmacol; 2018 Mar; 33(2):111-119. PubMed ID: 29064909
[TBL] [Abstract][Full Text] [Related]
16. Heroin addiction: beta-endorphin immunoreactivity in plasma increases during withdrawal.
Emrich HM; Nusselt L; Gramsch C; John S
Pharmacopsychiatria; 1983 May; 16(3):93-6. PubMed ID: 6310651
[TBL] [Abstract][Full Text] [Related]
17. [Modification of the pain threshold and beta-endorphin level in heroin addicts undergoing withdrawal].
Matera M; Virgilio A; Cassarino P; Cassarino S; Aguglia E; Rapisarda E
Riv Eur Sci Med Farmacol; 1988 Feb; 10(1):73-7. PubMed ID: 2978935
[No Abstract] [Full Text] [Related]
18. [A randomized, double-blind, controlled study: Ji-Tai tablet for the treatment of acute withdrawl syndrome of mild heroin dependence].
Wang Y; Tang C; Cheng S; Cui G; Zhang R; Zhang Z; Xie L; Lin Y; Hao W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Feb; 40(2):117-22. PubMed ID: 25769319
[TBL] [Abstract][Full Text] [Related]
19. PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users.
Shi J; Zhao LY; Copersino ML; Fang YX; Chen Y; Tian J; Deng Y; Shuai Y; Jin J; Lu L
Eur J Pharmacol; 2008 Jan; 579(1-3):160-6. PubMed ID: 17977528
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects.
Chawla JM; Pal H; Lal R; Jain R; Schooler N; Balhara YP
J Opioid Manag; 2013; 9(1):35-41. PubMed ID: 23709302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
